First AD

Second AD

SPORT Trial

Video content above is prompted by the following:

Supplements are often used by patients in replacement of LLT; however, data have shown that they are less effective in lowering LDL-C. Can you describe the SPORT trial and its findings?

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Video Series

From LDL-C to Lp(a): A Multispecialty Approach to Reducing the Rising Tide of Cardiovascular Disease

Pediatric lipid screening is crucial for early detection and management of dyslipidemia, which can prevent cardiovascular diseases later in life. Current guidelines recommend universal lipid screening for children between ages 9-11 and 17-21, with selective screening for those with risk factors. However, implementation remains inconsistent due to barriers such as lack of awareness and time constraints in clinical practice. To improve uptake, strategies include integrating screening into routine pediatric visits, utilizing electronic health records for reminders, and educating healthcare providers and families about the importance and benefits of early lipid screening.

Panelists discuss how the SPORT trial demonstrated the limited efficacy of dietary supplements compared with traditional lipid-lowering therapies in reducing LDL-C levels.

Prevalence of Cardiovascular Disease

AHA Guidelines and Patient Mortality 

Role of LDL-C in ASCVD

Pediatric Lipid Screening

Lp(a) in Pediatrics

DCRM Recommendations for Lipid Testing and LDL-C Management 

Other Lipid Biomarkers

LDL-C Management in Subpopulations

Cost Considerations for LDL Reduction Therapies

Familial Hypercholesterolemia Testing

Role of Lp(a) in ASCVD Risk

Data Analysis: State of LDL-C Control in Patients With ASCVD

Pediatric Lipid Treatment Recommendations

International Lipid Expert Panel Recommendations and RACING Trial

Novel Nonstatin LLTs for Lowering LDL-C and CVD Risk

CLEAR-Outcomes Data: Primary Prevention With Bempedoic Acid

Barriers Associated With Controlling LDL-C

Final Insights